Johan Frederik Mebus Meyer Christensen

Dr. Johan Frederik Mebus Meyer Christensen

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2025 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
JCJohan Frederik Mebus Meyer Christensen
Johan Frederik Mebus Meyer Christensen
SDSigne Wegmann Düring
Signe Wegmann Düring
Gesche JürgensGesche Jürgens
Gesche Jürgens
Aims: Patients with severe mental disorder and diabetes may be exposed to inappropriate polypharmacy increasing the risk of side effects and drug interactions. Although medication reviews may facilitate short‐term deprescribing, they are not known to affect clinical outcomes. We investigated whether implementing physician‐led medication reviews through interdisciplinary dialogue can change prescription patterns and improve pharmacological efficacy and tolerability in psychiatric outpatients with diabetes. Methods: Included in the study were 52 patients from an endocrinologist–psychiatrist outpatient clinic in Slagelse Region, Zealand, Denmark. Patients were allocated to an intervention group, where patients' pharmacological treatment was discussed at an interdisciplinary treatment conference based on a medication review conducted by a specialist in clinical pharmacology or a control group receiving standard care. All patients underwent psychometric testing, side effect screening, clinical interviews, and had drug regimens and biochemical test results extracted from the electronic health records at baseline and at 6 months follow up. Results: The trial was completed by 48 patients. Average time to follow up was 7 months (range 5–11 months). The intervention group had a median reduction of 1 drug (interquartile range [IQR] −4.00, 0.00) and 1 potentially inappropriate prescription (IQR –2.00, 0.00) compared to a median increase of 2 drugs (IQR 1.00, 3.00) and 2 potentially inappropriate prescriptions (IQR 0.00, 3.00) in the control group. The usage of both somatic and psychiatric drugs was reduced. We found no differences in clinical outcomes. Conclusion: Deprescribing can be achieved without worsening psychiatric symptoms in psychiatric outpatients by implementing physician‐led medication reviews through interdisciplinary dialogue. This study was registered on ClinicalTrials.gov : NCT (05243160).

15 December 2025 in Basic & Clinical Pharmacology & Toxicology
Verified
Journal Article
Closed access
JCJohan Frederik Mebus Meyer Christensen
Johan Frederik Mebus Meyer Christensen
AKAnne Kolbye
Anne Kolbye
Gesche JürgensGesche Jürgens
Gesche Jürgens

16 October 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
JCJohan Frederik Mebus Meyer Christensen
Johan Frederik Mebus Meyer Christensen
JJJonathan Hugo Jürgens-Lahnstein
Jonathan Hugo Jürgens-Lahnstein
AIAfrim Iljazi
Afrim Iljazi
SAStig Ejdrup Andersen
Stig Ejdrup Andersen
Morten DahlMorten Dahl
Morten Dahl
Gesche JürgensGesche Jürgens
Gesche Jürgens
Background: QT prolongation is a potential serious adverse drug reaction, and assessing the risk of QT-prolonging drugs is routinely included in psychotropic medication reviews. However, the actual clinical benefits of such assessments are unknown. We investigate whether QT prolongation (QTc value > 480 ms) manifests in psychiatric inpatients at risk of QT prolongation as identified by assessing drug regimens. Secondly, we test the predictive value of well-known risk factors for QT prolongation. Results: The median patient age was 49 years (IQR 34–64) for patients treated with a median of nine drugs (IQR 6–12) and a median QT-prolonging drug sum of three daily defined dosages (IQR 1.88–4.76). We extracted 290 ECGs for patients where pharmacist-led-medication reviews (PMRs) identified an increased risk of QT prolongation and 190 ECGs for patients with no such risk, identifying 33 cases of verified QT prolongation equally distributed between groups. Unadjusted regression analysis revealed that advanced age (OR 3.27 CI 95% 1.60–6.84) and cardiovascular comorbidity (OR 3.53 CI 95% 1.71–7.29) were associated with manifest QT prolongation, while the QT-prolonging drug load was not. Methods: We reviewed electronic health records (EHRs) of 799 psychiatric inpatients exposed to PMRs made from 1 September 2016 to 31 December 2018 in Region Zealand Denmark. Conclusions: Patients at risk of QT prolongation as identified by drug reviews rarely manifests with actual QT prolongation. Non-pharmacological risk factors seem to be better predictors for identifying patients with QT prolongation.

1 September 2025 in Wellcome Open Research
Verified
Journal Article
Open access
AEAnais Essilini
Anais Essilini
JCJohan Frederik Mebus Meyer Christensen
Johan Frederik Mebus Meyer Christensen
EWEmma Wallace
Emma Wallace
MFMichelle Flood
Michelle Flood
RFRóisín Friars
Róisín Friars
MWMary E. Walsh
Mary E. Walsh
Introduction Serotonin syndrome is a potentially lethal adverse drug reaction caused by exposure to one or more serotonin-elevating medications. Its burden is unknown due to the absence of official diagnostic criteria, under-reporting and symptom overlap with other syndromes. This overview of reviews aims to summarise published systematic review evidence on drugs and risk factors commonly associated with serotonin syndrome and to determine its incidence. Methods Searches will be conducted in Medline (OVID), Embase, the Cochrane Database of Systematic Reviews, PsycInfo and Epistemonikos. PROSPERO will also be searched for ongoing reviews. Systematic reviews reporting the incidence of serotonin syndrome in patients treated with at least one serotonin-elevating drug will be included. The quality of included systematic reviews will be assessed using the JBI’s critical appraisal checklist for Systematic Reviews and Research Syntheses. Two reviewers will independently conduct title/abstract screening and full text review. Data extraction will be conducted as a multi-stage process from the included systematic reviews as well as from eligible primary studies within systematic reviews, according to the overview objectives. The results will be synthesised both narratively and quantitatively using random effects models. We will present pooled estimates with 95% CIs for binary data and mean difference or standardised mean difference with 95% CIs for continuous data. The results will be presented in forest plots to assess their heterogeneity. Statistical heterogeneity will be assessed with I 2 statistics. Ethics and dissemination No ethical approval will be required. The results will be disseminated through open-access peer-review journals and conferences.

11 June 2026 in Basic & Clinical Pharmacology & Toxicology
Verified
Journal Article
Open access
JCJohan Frederik Mebus Meyer Christensen
Johan Frederik Mebus Meyer Christensen
ECElisabeth Mebus Meyer Christensen
Elisabeth Mebus Meyer Christensen
UCUlla Christensen
Ulla Christensen
SDSigne Düring
Signe Düring
GJGesche Jürgens
Gesche Jürgens
Background: We previously found that implementing medication reviews by a physician specialised in clinical pharmacology at interdisciplinary conferences with prescribing physicians and nurses led to a relative reduction in the number of drugs and potentially inappropriate prescriptions (PIPs) in psychiatric outpatients with diabetes. Adhering to the framework of health technology assessments (HTAs) and to facilitate direct implementation, we subsequently demonstrated the intervention as cost neutral. Aim: This study aimed to identify contextual, organisational and interprofessional barriers and facilitators in implementing the intervention focusing on nurses' role at interdisciplinary conferences. Methods: We conducted semi‐structured interviews with available staff and four patients from the intervention group. We conducted a primary thematic analysis with HTA as a framework, while a secondary analysis situated the themes into a contextual understanding. Results: Interdisciplinary dialogue tailors pharmacological recommendations to patients adhering to clinical pragmatism rather than generic prescription guidelines. It enables professional growth and reciprocal learning and levels out an inherent doctor–nurse hierarchy. However, when conferences were online or hybrid, nurses did not benefit to the same extent and had the feeling of being set aside. Conclusion: Interdisciplinary medication reviews in psychiatry may improve the clinical relevance of pharmacological decision‐making and level out an inherent physician–nurse hierarchy in psychiatry.

13 September 2025 in Infectious Diseases
Verified
Journal Article
Open access
JCJohan Frederik Mebus Meyer Christensen
Johan Frederik Mebus Meyer Christensen
RMRikke Meyer
Rikke Meyer
MHMadlene Holmqvist
Madlene Holmqvist
KCKatherine Carlson
Katherine Carlson
SPSebastian Palmqvist
Sebastian Palmqvist
SASidse Marie Arnfred
Sidse Marie Arnfred
While patients with post-COVID syndrome (PCS) suffer from cognitive deficits few studies directly compare patients with PCS to subjects recovered after an infection with the 'Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)'. To investigate cognitive performance adjusting for age, increasing body-mass-index (BMI), smoking, years of education, gender and hospitalisation while infected in patients with PCS compared to controls fully recovered. Secondly, to stratify cognitive performance based on the SARS-CoV-2 virus strain (variant of concern 'VOC') causing the infection. Thirdly, to assess whether patients with PCS have increased levels of psychological distress and affected hand grip strength as both are associated with cognitive performance. A Danish-Swedish case-control study we recruited adult patients (18-75 years) with PCS from long-COVID outpatient clinics in Region Zealand Denmark and Skåne County Sweden. Participants had confirmed SARS-CoV-2 infection >12 weeks prior to inclusion and healthy control subjects had recovered completely. All study participants were exposed to cognitive tests, Kessler's psychological distress scale (K10) and tested with a hand-dynamometer. Recruiting 181 cases and 155 control subjects, patients with PCS had reduced cognitive performance scores on all domains though hardly clinically significant. Reduced processing speed was impacted the most with patients infected early in the pandemic exhibiting greater deficits. PCS was associated with reduced cognitive processing speed compared to fully recovered controls with those infected early in the pandemic having greater deficits. Psychological distress and hand grip strength were affected in patients with PCS, but not decisively associated with cognitive performance.